NLRP3 and atherosclerosis: In addition, Jiang et al. demonstrated that berberine reduced the activation of the NLRP3 inflammasome via the ROS-dependent pathway, which provided the evidence for the hypothesis that berberine alleviated NLRP3 inflammasome activation and reduced IL-β secretion from macrophages, showing an important therapeutic target in atherosclerosis therapy [103].